An open-label, prospective study to assess the efficacy, safety and tolerability of 36 weeks lamotrigine in the prevention of mood episodes in subjects with bipolar disorder, who are in remission following a manic/hypomanic index episode or a depressive index episode
Latest Information Update: 06 Sep 2023
At a glance
- Drugs Lamotrigine (Primary)
- Indications Bipolar disorders
- Focus Registrational; Therapeutic Use
- Sponsors GSK
- 08 Nov 2006 New trial record.